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Introduction. Pulmonary arterial hypertension (PAH) is a major cause
of mortality in SSc. NT-proBNP may be a useful biomarker of prevalent
PAH but its role in screening for incident PAH has not been evaluated.
Methods. Patients recruited into the Australian Scleroderma Cohort
Study undergo annual echocardiography, pulmonary function tests
(PFTs), 6-min walk test (6MWT) and have serum NT-proBNP measured
(ElecsysproBNP II). The diagnosis of PAH is based on Dana point
criteria at right heart catheterization (RHC). Patients with LV dysfunc-
tion or eGFR <30 ml/min were excluded from this study. Four clinical
groups were selected. Group 1 (n¼20) had definite PAH with pre-
treatment sera assayed. Group 2 (n¼30) were considered ‘at risk’ for
PAH based on (i) sPAP on echo >36 mmHg, (ii) FVC/DLCO% >1.6 and
no significant ILD, (iii) DLCO <50% or (iv) resting mPAP of 20–25 mmHg
at RHC. Group 3 (n¼19) had interstitial lung disease (ILD) but no
evidence of PAH on echo or RHC. Group 4 (n¼31) were SSc patients
without cardiopulmonary disease. Analysis of variance with two-group
comparisons were used to determine differences in clinical character-
istics and NT-proBNP level among groups. Simple and multiple linear
regression were used to determine correlates of NT-proBNP. ROC
curve analysis was performed to determine the optimal NT-proBNP
threshold for detection of PAH.
Results. Patient characteristics are summarized in Table 1. As seen
in Fig. 1, patients in Group 1 (PAH) had significantly higher mean
NT-proBNP levels than patients in Group 4 (SSc controls; P<0.0001).
In addition, patients in Group 2 (‘at risk’) had significantly higher
NT-proBNP levels than those in Group 4 (SSc controls; P¼0.008).
In simple linear regression, NT-proBNP was positively correlated
with echo parameters (P< 0.0001). Among patients with PAH, NT-
proBNP was positively correlated with mPAP on RHC (adjusted
estimate¼0.048, 95% CI 0.01, 0.09, P¼0.019), independently of
corrected DLCO, FVC/DLCO% ratio and 6MWD. An NT-proBNP cut-
point of> 189.2 pg/ml had a likelihood ratio of 26.4 for presence of
PAH (c-statistic¼0.9; sensitivity 85%; specificity 97%). An NT-
proBNP level <82.9 pg/ml had a likelihood ratio of 6.8 for exclusion
of PAH (sensitivity 67.7%, specificity 90%).
Conclusions. Our findings suggest that in absence of LV dysfunction,
NT-proBNP is a useful screening biomarker for PAH in SSc, with levels
>189.2 pg/ml and <82.9 pg/ml defining patients with a high and
low likelihood of PAH, respectively. Further prospective studies are
required in unselected patients in order to confirm these findings.
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TABLE 1.
Group 1, PAH Group 2, at risk Group 3, ILD Group 4, SSc controls P-value
Number 20 90 19 31 NA
Sex, n (%)
Female 16 (80) 25 (83) 14 (74) 31 (100) 0.041
Male 4 (22) 5 (17) 5 (26) 0
Disease subtype, n
Limited 16 28 6 13 22 <0.0001
Diffuse 3 2 0 8
MCTD 1 0 1
Age at SSc onset, mean (S.D.), years 42 (114) 52 (15) 40 (16) 41 (13) 0.011
Age at time of study, mean (S.D.), years 62 (10.3) 66 (11.8) 51.1 (12.7) 48.4 (10) <0.0001
Disease duration at study, mean (S.D.), years 20.4 (12.8) 14.5 (10.4) 10.8 (7.9) 7.6 (7.2) 0.0001
Echo parameters, mean (S.D.)
TR velocity, ms/s 3.81 (0.69) 2.95 (0.28) 2.58 (0.38) 2.20 (0.18) <0.0001
sPAP, mmHg 65.25 (27.82) 43.8 (7.16) 33.54 (7.73) 26.2 (2.57) <0.0001
RHC parameters, mean (S.D.)
mPAP, mmHg 39.50 (12.36) NA NA NA NA
mftAP, mmHg 9.94 (2.96)
PVR 6.16 (3.10)
6MWD, m 335 (96) 401 (114) 458 (84) 502 (74) 0.0001
WHO-FC
1 0 5 2 22 <0.0001
II 3 10 10 4
III 12 13 6 2
IV 3 0 1 0
PFT
FVC, per cent predicted 71.6 (24.7) 100.6 (19.5) 71 (14.6) 100.9 (13.12) <0.0001
Corr DLCO% 43.5 (12.2) 59.8 (14.7) 47.4 (13.8) 1.48 87.2 (14.3) <0.0001
fvC:0lCO ratio 1.68 (0.47) 1.75 (0.46) (0.35) 1.17 (0.19) <0.0001
NT-ProBNP, pg/ml 1791 (2509) 278 (243) 133 (87) 75 (43) <0.0001
FIG. 1 NT-proBNP level according to group.
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Background. Pulmonary arterial hypertension (PAH) is one of the
leading causes of death in SSc. Management of patients with SSc-
associated PAH (SSc-PAH) is rapidly evolving and recently reported
survival is better than in historical cohorts (albeit still unsatisfactory).
However, no data on incident patients are available since 2006.
Aims and objectives. This study describes the characteristics and
outcome of SSc patients prospectively enrolled in the multicentre
French PAH registry since 2006
Methods. SSc patients (according to American College of
Rheumatology and/or LeRoy and Medsger’s criteria) enrolled in the
registry between January 2006 and November 2009 were prospec-
tively included if they had a pre-capillary PAH confirmed by right heart
catheterization <1 year prior to enrolment (incident patients with newly
diagnosed PAH). Patients with interstitial lung disease (ILD) on high-
resolution CT (HRCT) were included if forced vital capacity (FVC)
>70%.
Results. A total of 100 SSc patients were included; 81% were women.
Mean age at PAH diagnosis was 65 (12) years, 86% of patients had
lcSSc, 80% were in New York Heart Association functional class
(NYHA FC) III or IV and 15% had ILD on HRCT, mean FVC and the ratio
of diffusing capacity of the lung for carbon monoxide/alveolar volume
(DLCO/VA) were 92 (20%) and 54 (20%) of predicted values,
respectively. At baseline, mean 6-min walk distance (6MWD) was
266 (119)m and mean pulmonary vascular resistances were 674 (346)
dyn.s.cm5. Median follow-up was 2.4 years with 45 deaths observed;
overall survival was 86, 72, 52 and 36% at 1, 2, 3 and 4 years,
respectively. Univariate analysis identified age (HR¼1.04), NYHA
functional class (HR¼4,03), desaturation after 6-min walk test
(HR¼0.90), DLCO/VA (HR¼0.98), presence of an ILD (HR¼ 2.63)
and cardiac index (HR¼0.53) as factors prognostic of survival. Other
parameters did not reach statistical significance (P< 0.05), including
SSc subtype and mPAP.
Conclusions. These results confirm the poor prognosis for incident
and newly diagnosed SSc-PAH patients even in the modern era of
treatment. NYHA functional class, age and presence of an ILD at the
diagnosis of PAH were important prognosis factors. Poor right
ventricular haemodynamic function and desaturation during the 6-
min walk test were also associated with mortality. As 80% of patients
are still diagnosed with an NYHA function Class III/IV which appears as
one of the most important prognosis factor, screening allowing an
earlier diagnosis should be a priority.
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Background. Pulmonary hypertension (PH) in SSc may have different
causes, the most common being pulmonary arterial hypertension
(PAH), PH secondary to interstitial lung disease and PH secondary lo
left ventricular (LV) dysfunction. Although in most patients PH is
diagnosed late in the disease course, development of all types of PH
has been also described in early patients. The EUSTAR database
allows us to analyse the clinical associations of PH, in a large number
of early SSc patients.
Objective. To identify the clinical associations of HP detected by
echocardiography (PH-echo), in a large group of recently diagnosed
SSc patients.
Patients and methods. EUSTAR collects prospectively the Minimal
Essential Data Set (MEDS), on all sequential patients fulfilling the ACR
diagnostic criteria in participating centres. Patients with disease
duration of <3 years at the first EUSTAR entry were selected, and
only baseline data from the first visit were analysed. Binary logistic
regression, chi-square ant t-test were used to analyse differences
between groups with or without PH-echo.
Results. From 1072 patients (19% men), 482 had diffuse and 590 had
limited disease. Mean age at entry was 53 (14) years, and at first non-
Raynaud symptom 51 (16) years. Mean disease duration was 18 (6)
months and time between the onset of Raynaud and first non-Raynaud
symptom was 3 (7) months. PH-echo was present in 184 (18%)
patients. PH was highly associated (P<0.0001 for all) with older age,
lung involvement (lung fibrosis, restriction, low DLCO), cardiac
involvement (cardiac blocks, LV systolic and diastolic dysfunction)
and very active disease (EUSTAR activity index, acute-phase
response, ischaemic ulcers, joint contractures, muscular atrophy,
high mRSS). To a lesser extent is also associated with renal
involvement (renal crisis P¼ 0.01; high blood pressure P¼0.05;
proteinuria P< 0.0001). The results are similar when the subgroups
of diffuse disease, limited disease, males, females or patients with
disease duration <1 year were analysed.
Conclusions. In early SSc patients, PH-echo is present in patients
with very active disease, showing cardiac, lung and renal involvement.
Although some of these patients might present true PAH, others may
have PH secondary to lung or left heart involvement. Since treatment
for PH of different causes is not the same, our findings emphasize
the need to perform right heart cathetherization to clearly diagnose
the cause of PH in every SSc patient.
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Introduction. The PHAROS registry is a prospective observational
longitudinal cohort study, designed to understand the natural history of
pulmonary hypertension (PH) in SSc.
Method. Pre-PH is defined by one of the following entry criteria:
echocardiogram systolic pulmonary arterial pressure (sPAP) of
>40 mmHg or diffusion lung capacity of carbon monoxide (DLCO)
<55% predicted or the ratio of per cent forced vital capacity (FVC) /
%DLCO >1.6. Patients were followed biannually. Right heart catheter-
ization (RHC) was performed if PH was suspected, and confirmed if
the mean pulmonary arterial pressure (mPAP) 25 mmHg. Descriptive
statistics and Kaplan–Meier estimate of the time to PH diagnosis were
performed.
Results. There were 246 pre-PH subjects enrolled between May 2005
and August 2011. Patients were followed for a mean of 2.5 (1.2) years.
Thirty-two subjects developed PH confirmed during follow up. Based
on WHO classification at Dana Point, 19 were classified as WHO
Group 1 PAH and 13 as WHO Groups 2 and 3 PH. Fig. 1 shows the
time to PH was 11% at 2 years, 15% at 3 years and 30% at 4 years.
There were no statistically significant demographic features in the 32
PHþ subjects compared with the Non-PH group (Table 1). At baseline,
the PHþ group had a significantly lower 6-min walk distance and
significantly more exercise-induced hypoxia than the non-PH group.
The PHþ group had lower entry %DLCO and higher FVC%/DLCO %,
though this did not reach statistical significance.
The mean echo sPAP at entry in the PHþ group was significantly higher
(OR¼2.37, 95% CI 1.1, 5.1), and subsequently increased to 54.1
(18.0) mmHg, leading to RHC. Thirteen of these patients [whose mean
echo sPAP was 47 (10.3) mmHg] had an initial normal RHC [mPAP
21.2 (2.8) mm Hg], but subsequently developed PH. Overall, 66 of the
246 patients had a normal RHC; their mean echo sPAP was 40 (11.3)
mmHg which was significantly higher than the RHC sPAP [30.2 (5.6)
mmHg, P<0.001].
Conclusion. PH was confirmed in 13% of these high-risk patients,
with 30% developing PH 4 years after entry. Exercise hypoxia and an
entry echo sPAP> 40 were strongly associated with future PH.
However, frequent false elevations in echo sPAP required an RHC to
confirm PH.
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
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Mean age at entry, years 56.2 (11.2) 59.3 (9.0) 0.08
Gender, female, n (%) 186 (87.3) 27 (84.4) 0.86
Race, Caucasian, n (%) 156 (73.2) 21 (65.6) 0.62
Mean time from onset of
Raynaud’s, years
11.5 (11.6) 11.9 (10.2) 0.84
Mean time from onset of
non-Raynaud’s, years
10.1 (10.9) 10.0 (8.6) 0.9
SSc subtype, limited, n (%) 133 (65.2) 20 (62.5) 0.91
Antibody, n (%) (n¼ 185) (n¼ 31)
ACA 46 (24.9) 9 (29.0) 0.65
Anti-Scl70 34 (18.4) 2 (2.5) 0.12
Isolated nucleolar pattern 28 (15.1) 9 (29.0) 0.07
Mean walk distance, m 418.1 (121.8) 352.3 (153) 0.03*
Oxygen saturation <92%
with exercise, n/N (%)
31/132 (23.5) 14/25 (56) 0.002*
(n¼ 209) (n¼ 31)
Mean %DLCO 51.2 (18.6) 46.4 (17.3) 0.18
Mean FVC%/DLCO% 1.78 (0.59) 2.0 (1.11) 0.19
Patients meeting PFT criteria
at entry, n/N (%)
128/209 (61.2) 25/31 (80.6) 0.06
(n¼ 200) (n¼ 31)
Mean echo sPAP, mmHg 38.3 (8.8) 44.3 (9.7) 0.001*
Patients meeting echo criteria
at entry, n (%)
62 (31.0) 16(51.6) 0.04*
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Background. Patients with SSc are at risk of developing pulmonary
hypertension (PH), which is associated with a poor prognosis.
Exercise-Doppler echocardiography (EDE) enables identification of
exercise-induced increase in pulmonary artery systolic pressure
(PASP) and may provide a thorough non-invasive haemodynamic
evaluation.
Aim. To evaluate the clinical and echocardiographic determinants
of exercise-induced increase in PASP, assessed by EDE, in a large
population of SSc patients.
Methods. We selected 164 SSc patients [age 58 (13) years, 91%
females] with normal resting PASP (<40 mmHg), who underwent a
comprehensive 2D and Doppler echocardiography, and a graded
bicycle semi-supine EDE. Pulmonary vascular resistances (PVRs) were
estimated non-invasively from tricuspid regurgitant maximal velocity
and right ventricular outflow tract time-velocity integral. A cut-off value
of PASP 50 mmHg and PVR 3.0 Wood Units (WUs) at peak exercise
was considered as indicative of significant exercise-induced increase
in PASP and PVR, respectively.
Results. Sixty-nine (42%) patients showed a significant exercise-
induced increase in PASP. Among them, peak PVR 3 WU were
present only in 11% of patients, which is 5% of the total population.
Univariate analysis showed that age, presence of interstitial lung
disease (ILD) and both right and left diastolic dysfunction are
predictors of peak PASP 50 mmHg, but none of these parameters
predict elevated peak PVR.
Conclusions. Exercise-induced increase in PASP occurs in almost
one-half of SSc patients with normal resting PASP. Peak exercise
PASP is affected by age, ILD and right and left ventricular diastolic
dysfunction, and only in 5% of the patients is associated to an
increase in PVR during exercise, suggesting heterogeneity of the
mechanisms underlining exercise-induced PH in SSc.
 The Author 2012. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
FIG. 1 Probability of developing PH vs years in study (n¼218, with
95% CI). X-axis: years in the study; Y-axis: probability of developing
PAH/PH.
FIG. 1
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